The Benefit of DLBS3233 as Add-on Therapy for Symptomatic Painful Diabetic Neuropathy: Case Series

Rizaldy Taslim Pinzon; Abraham Al Jody; Nicholas Adriel Pinzon

doi:10.56951/rhjkcb40

The Benefit of DLBS3233 as Add-on Therapy for Symptomatic Painful Diabetic Neuropathy: Case Series

Penulis

Rizaldy Taslim Pinzon Neurology Department, School of Medicine, Duta Wacana Christian University, Yogyakarta
Abraham Al Jody Neurology Department, School of Medicine, Duta Wacana Christian University, Yogyakarta
Nicholas Adriel Pinzon Neurology Department, School of Medicine, Duta Wacana Christian University, Yogyakarta

DOI:

https://doi.org/10.56951/rhjkcb40

Kata Kunci:

painful diabetic neuropathy, pain reduction, diabetes, DLBS3233

Abstrak

Symmetrical painful diabetic neuropathy (PDN) is a highly prevalent form of diabetic peripheral neuropathy with significant
morbidity. Despite its high prevalence, the optimal treatment of this condition remains a clinical challenge. There was an
emergence need for add-on therapy that more focused on the dimensions of inflammation and toxic oxidative stress.
Previous evidences from placebo-controlled studies have shown that opioids, antiepileptic, and antidepressant drugs
are effective for alleviating PDN symptoms. In many cases, safety issues regarding potential side effects of those drugs
limit the optimal use of the medications. We report case series of painful diabetic neuropathy in type 2 diabetic patients.
DLBS3233 was given as add-on therapy to standard oral antidiabetic medication or insulin and adjuvant analgesics for
all patients. After 3 months follow up, there was modest pain reduction and improvement in blood glucose control in all
patients. DLBS3233 was well tolerated in all patients.

Unduhan

Baca Selengkapnya

Referensi

1. Pop-Busui R, Ang L, Boulton AJM, Feldman EL, Marcus RL, Mizokami-Stout K, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy. ADA Clin. Compend. 2022;2022:1–32.

2. Smith S, Normahani P, Lane T, Hohenschurz-Schmidt D, Oliver N, Davies AH. Prevention and management strategies for diabetic neuropathy. Life 2022;12:1185.

3. Chao CC, Hsieh SC, Yang WS, Lin YH, Lin WM, Tai TY, et al. Glycemic control is related to the severity of impaired thermal sensations in type 2 diabetes. Diabetes Metab Res Rev. 2007;23:612–20.

4. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.

5. Sloan G, Alam U, Selvarajah D, Tesfaye S. The treatment of painful diabetic neuropathy. Curr Diabetes Rev. 2022;18(5).

6. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012;6:CD007543.

7. Meijer JG, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care 2003;26 (3):697–701.

8. Bhokare KH and Upaganlawar AB. Neuroprotective effects of Lagerstroemia speciosa L. extract (banaba leaf extract) in streptozotocine-induced painful diabetic neuropathy in laboratory rats. Pharmacologia 2016;7:9-15.

9. Aljarba NH, Hasnain MS, Alkahtane AA, AlghamdI H, Alkahtani SH. Lagerstroemia speciosa extract ameliorates oxidative stress in rats with diabetic nephropathy by inhibiting AGEs formation. Journal of King Saud University – Science 2021;33(6):101493.

10. Manaf A, Tjandrawinata R, Malinda D, Susanto L. Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa. Drug Des Devel Ther. 2016;10:1279-89.

11. Nailufar F, Tandrasasmita OM, Tjandrawinata RR. DLBS3233 increases glucose uptake by mediating upregulation of PPARγ and PPARδ expression. Biomed Prevent Nutr. 2011;1(2):71–8.

12. Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR. Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression. Int J Gen Med. 2011;4:345.